HOTer+ ABC

Breast cancer is the second most common cancer in the world and the most frequent cancer among women. There were 6620 new cases diagnosed in 2011 in the Czech Republic (123.9 cases per 100 000 women). Huge advance in diagnostics and treatment of breast cancer has been made in recent years. However, breast cancer still has a significant mortality rate and is the most common cause of cancer related death in Czech women. [1, 2]

Hormonal treatment is preferred option and is recommended in women with hormone sensitive breast cancer (ESMO, NCCN and Czech guidelines) regardless presence of visceral metastases. Chemotherapy is recommended in patients with rapidly progressive disease or in case of hormonal resistance. Sequential use of several hormonal treatment modalities is encouraged. [3, 4, 4]

There has been a retrospective chart review published from five European countries (Belgium, France, Germany, The Netherlands, and Sweden). The review has been done in 355 postmenopausal women with HR positive, HER2 negative advanced BC who progressed on ≥1 line of HT (adjuvant or advanced) and completed ≥1 line of chemotherapy for advanced BC. More than 30% of patients received chemotherapy in 1st line and only 22% of patients received HT as the 2nd line treatment. Authors conclude that study suggests that the guideline-recommended use of multiple HT lines is open to interpretation. [5]

As there are no published national data on use of hormonal therapy in ER+ advanced breast cancer, this observational study in the Czech Republic has been designed in order to acquire better knowledge of advanced breast cancer management.

Primary objective of the project:

• To show treatment patterns in postmenopausal women with ER+, HER-2 negative advanced breast cancer in the Czech Republic.

Secondary objectives of the project:

• To assess time to change of therapy in particular lines of therapy in postmenopausal women with ER+, HER-2 negative advanced breast cancer in real world practice.

Other important information:

• Partners: approximately 40 health care facilities in the Czech Republic

References

1. Zdravotnická ročenka České republiky / Czech Health Statistics Yearbook. Prague: Institute of Health Information and Statistics of the Czech Republic, 2013. Available from WWW: http://www.uzis.cz/system/files/zdrroccz2013.pdf (accessed 16 February 2016).
2. Breast Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available from WWW: http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp (accessed 16 February 2016).
3. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology 2014; 25(10): 1871-1888. doi: 10.1093/annonc/mdu385.
4. NCCN guidelines. Breast Cancer. Version 1.2016. Available from WWW: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 15 February 2016).
5. Zhoubný novotvar prsu (C50) [article in Czech language]. Available from WWW: http://www.linkos.cz/informace-pro-praxi/modra-kniha/12-zhoubny-novotvar-prsu-c50/ (accessed 16 February 2016).